{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:49:08Z","timestamp":1782546548228,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd013604","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000}}],"reference-count":41,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013604.pub2","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T11:25:02Z","timestamp":1669634702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer"],"prefix":"10.1002","volume":"2022","author":[{"given":"Yu","family":"Uneno","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Oncology; Graduate School of Medicine, Kyoto University; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Imura","sequence":"additional","affiliation":[{"name":"Department of Health Informatics; School of Public Health in Graduate School of Medicine, Kyoto University; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Makuuchi","sequence":"additional","affiliation":[{"name":"Hematology; Graduate School of Medicine, Osaka Metropolitan University; Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tochitani","sequence":"additional","affiliation":[{"name":"Department of Heathcare Epidemiology; School of Public Health in the Graduate School of Medicine, Kyoto University; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Soseikai General Hospital; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013604.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"Aguado","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/bmt.2010.38","article-title":"Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT","volume":"45","author":"Blennow","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1002\/14651858.CD013604.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013604.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bmt.2008.355","article-title":"A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT","volume":"43","author":"Hebart","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1002\/14651858.CD013604.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(13)70076-8","article-title":"Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial","volume":"13","author":"Morrissey","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013604.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/j.ijid.2011.01.011","article-title":"Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study","volume":"15","author":"Tan","year":"2011","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.12659\/msm.897596","article-title":"Preemptive antifungal therapy for febrile neutropenic hematological malignancy patients in China","volume":"22","author":"Yuan","year":"2016","journal-title":"Medical Science Monitor"},{"issue":"8","key":"10.1002\/14651858.CD013604.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1200\/JCO.19.01916","article-title":"D-index-guided early antifungal therapy versus empiric antifungal therapy for persistent febrile neutropenia: a randomized controlled noninferiority trial","volume":"38","author":"Kanda","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013604.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-3062.2006.00123.x","article-title":"Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy","volume":"8","author":"Pauw","year":"2006","journal-title":"Transplant Infectious Disease"},{"issue":"3","key":"10.1002\/14651858.CD013604.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jiph.2018.12.006","article-title":"Epidemiology and source of infection in patients with febrile neutropenia: a ten-year longitudinal study","volume":"12","author":"Al-Tawfiq","year":"2019","journal-title":"Journal of Infection and Public Health"},{"issue":"2","key":"10.1002\/14651858.CD013604.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jac\/dkm463","article-title":"False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation","volume":"61","author":"Asano-Mori","year":"2008","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD013604.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008273.pub2","article-title":"Information interventions for orienting patients and their carers to cancer care facilities","author":"Chan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013604.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12879-017-2263-6","article-title":"Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013604.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ajcp\/72.4.617","article-title":"Opportunistic fungal infection among cancer patients. A ten-year autopsy study","volume":"72","author":"Cho","year":"1979","journal-title":"American Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0017|cit17","unstructured":"Covidence Veritas Health Innovation 2021"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013604.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013604.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.2214\/ajr.185.3.01850608","article-title":"Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients","volume":"185","author":"Escuissato","year":"2005","journal-title":"American Journal of Roentgenology"},{"issue":"4","key":"10.1002\/14651858.CD013604.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD013604.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"e0140930","DOI":"10.1371\/journal.pone.0140930","article-title":"Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia","volume":"10","author":"Fung","year":"2015","journal-title":"PLoS One"},{"issue":"24","key":"10.1002\/14651858.CD013604.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0025|cit25","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0026|cit26","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/PDF\/v5.2\/chapter-08"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0027|cit27","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. (updated February 2022) Cochrane, 2022\u00a0 Available from www.training.cochrane.org\/handbook"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013604.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of fever in neutropenic patients with different risks of complications","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013604.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"23","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013604.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/myc.12928","article-title":"Dermatological manifestations of fungal infection in patients with febrile neutropaenia: a review of the literature","volume":"62","author":"Maddy","year":"2019","journal-title":"Mycoses"},{"issue":"3","key":"10.1002\/14651858.CD013604.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3324\/haematol.2012.061952","article-title":"The role of antifungal treatment in hematology","volume":"97","author":"Maertens","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0032|cit32","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"12","key":"10.1002\/14651858.CD013604.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013604.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013604.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0036|cit36","unstructured":"Natinal Cancer Instittute Common terminology criteria for adverse events (CTCAE) v5.0 Available at ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"issue":"1","key":"10.1002\/14651858.CD013604.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0038|cit38","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"issue":"34","key":"10.1002\/14651858.CD013604.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013604.pub2-BIB0040|cit40","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"28","key":"10.1002\/14651858.CD013604.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T22:10:58Z","timestamp":1712095858000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013604.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013604.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}